

# Study on the Quality of Life Among Adolescents With Attention Deficit/Hyperactivity Disorder (QuaVAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. [Know the risks and potential benefits](#) of clinical studies and talk to your health care provider before participating. Read our [disclaimer](#) for details.

ClinicalTrials.gov Identifier: NCT03719950

Recruitment Status : Not yet recruiting

First Posted : October 25, 2018

Last Update Posted : October 25, 2018

See **Contacts and Locations**

## Sponsor:

Centre Psychothérapique de Nancy

## Information provided by (Responsible Party):

Centre Psychothérapique de Nancy

## • Study Details

- [Tabular View](#)
- [No Results Posted](#)

- [Disclaimer](#)
- [How to Read a Study Record](#)

## Study Description

Go to ▼

Brief Summary:

Attention Deficit Hyperactivity Disorder (ADHD) with a overall prevalence of 5.3% is one of the most common neurobehavioral disorders in children. In the foreign literature, many studies bring to light in children and adolescents the negative impact of ADHD on overall quality of life. Some of these studies were able to identify the fact that the higher the age of ADHD children or adolescents, the lower the quality of life. Currently, to our knowledge, only a few European studies have demonstrated the negative impact of ADHD on the quality of life of children and adolescents. In addition, these studies used only questionnaires intended for parents and not for children or adolescents.

During a regular follow-up consultation with their referent child psychiatrist, adolescents accompanied by at least one of their parents will be informed of the modalities of our study. A newsletter will be delivered to parents and one to the adolescent. If neither the adolescent nor the parents is opposed to participate, the child psychiatrist will register the patient on the list of study participants. He will also fill out a medico-social information sheet about the adolescent as to summarize the data in the medical record. At the end of this consultation, in the waiting room, adolescents will answer questionnaires KIDSCREEN-27 and MSPSS; their parents will complete the CBCL questionnaire. These questionnaires will be handed to the secretary who will put them back in the patient's record. The KIDSCREEN-27, MSPSS and CBCL questionnaires as well as the medico-social information sheet will be source documents. The principal investigator or one of the associates investigators will complete the case report form from these source documents. For this purpose the data will be entered anonymously into a data entry software on a computer server secured by the Centre Psychothérapique de Nancy (CPN). Then, anonymous data from the software will be forwarded to Dr. Epstein of the Clinical Investigation Center for statistical analysis. The study will begin when the favourable opinion of the Ethical Research Committees will be obtained and the study will last one year.

Condition or dis

Attention Deficit Hyperactivity Disorder

## Detailed Description:

Cross-sectional, descriptive epidemiological study based on single-centre trials

## Study Design

Go to ▼

Study Type : Observational

Estimated Enrollment : 100 participants

Observational Model: Other

Time Perspective: Cross-Sectional

Official Title: Monocentric Study on the Quality of Life Among Adolescents With Attention Deficit/Hyperactivity Disorder

Estimated Study Start Date : October 2018

Estimated Primary Completion Date : October 2019

Estimated Study Completion Date : October 2019

## Resource links provided by the National Library of Medicine

[MedlinePlus](#) related topics: [Attention Deficit Hyperactivity Disorder](#)

[U.S. FDA Resources](#)

## Groups and Cohorts

Go to ▼

## Outcome Measures

Go to ▼

### Primary Outcome Measures :

1. The KIDSCREEN-27 [ Time Frame: Day 0 (=day of inclusion = the only visit of the study) ]

A shorter version of KIDSCREEN-52 which is Health-Related Quality of Life Questionnaire for Children and Adolescents aged from 8 to 18 years The adolescent will consult his child psychiatrist and after he will answer to the questionnaire KIDSCREEN-27 during estimated time of fifteen minutes.

### Secondary Outcome Measures :

1. The Child Behavior Check List (CBCL) [ Time Frame: Day 0 (=day of inclusion = the only visit of the study) ]

The Child Behavior Check List assess behavioral or emotional psychopathological traits of children and adolescents aged 4 to 18 years. It composed of 118 items. The adolescent will consult his child psychiatrist and the parents will complete the Child Behavior Check List during about twenty minutes

2. The Multidimensional Scale of Perceived Social Support (MSPSS) [ Time Frame: Day 0 (=day of inclusion = the only visit of the study) ]

The MSPSS is a self-administered questionnaire designed to measure perceived social support. Composed of 12 items, the MSPSS measures perceived social support from three sources: family, friends and significant others. The adolescent will consult his child psychiatrist and after he will answer the MSPSS during about five minutes

## Eligibility Criteria

Go to ▼

### Information from the National Library of Medicine

*Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, [Learn About Clinical Studies](#).*

Ages Eligible for Study: 12 Years to 18 Years (Child, Adult)  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  
Sampling Method: Non-Probability Sample

### Study Population

Adolescents (12 to 18 years old) with diagnosis of ADHD followed during regional child psychiatric consultation at Child department of Nancy University Hospital

### Criteria

Inclusion Criteria:

- Adolescents aged 12 to 18 years
- Diagnosis of ADHD (F 90.0) ascertained by a child psychiatry according to CIM-10 criteria
- Seen by a child psychiatrist in consultation and accompanied by at least one of their parents
- Adolescents and at least one parent who has received enlightened information about the study
- Non-opposition to participate in the study gathered from at least one of their parents
- Patient affiliated or beneficiary of a social security scheme

Exclusion Criteria:

- Illiteracy of the parents or the adolescents
- Difficulties to understand french for the parents or the adolescents

### Contacts and Locations

Go to ▼

### Information from the National Library of Medicine

*To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.*

*Please refer to this study by its [ClinicalTrials.gov](#) identifier (NCT number): **NCT03719950***

### Contacts

Contact: Marie TRESSE +33383154850 [marie.tresse@cpn-laxou.com](mailto:marie.tresse@cpn-laxou.com)

Contact: Tatiana DABROWSKI +33383925349 [tatiana.dabrowski@cpn-laxou.com](mailto:tatiana.dabrowski@cpn-laxou.com)

### Sponsors and Collaborators

Centre Psychothérapique de Nancy

## Investigators

Principal Investigator: Vanessa WOLFF Centre Psychothérapique de Nancy

## More Information

Go to ▼

Responsible Party: Centre Psychothérapique de Nancy  
ClinicalTrials.gov Identifier: [NCT03719950](#) [History of Changes](#)  
Other Study ID Numbers: RIPH 2018-01  
First Posted: October 25, 2018 [Key Record Dates](#)  
Last Update Posted: October 25, 2018  
Last Verified: October 2018

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No

Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Disease  
Attention Deficit Disorder with Hyperactivity  
Hyperkinesis  
Pathologic Processes  
Attention Deficit and Disruptive Behavior Disorders  
Neurodevelopmental Disorders

Mental Disorders  
Dyskinesias  
Neurologic Manifestations  
Nervous System Diseases  
Signs and Symptoms